PBN Leaders & Achievers Awards 2026
GLENN ROBERTELLI
RI Bio executive director
Glenn Robertelli has spent 25 years building things that didn’t yet exist. Now he’s pivoting from building companies to building an ecosystem. Since July 2024, he has led RI Bio, Rhode Island’s premier life sciences trade organization, connecting major companies such as Johnson & Johnson, Amgen Inc. and Vertex with universities, the R.I. Life Science Hub and state government to grow the sector. It’s a shift from operator to convener, drawing directly on his technical background in some of the more ambitious corners of health technology.
Seifert Systems Invests in Energy Efficiency to Strengthen Operations
For manufacturers, energy is more than just another operating expense. It plays a critical role…
Learn More
“Instead of building one company, I get to help build the conditions where the next 20 breakthroughs can happen … here in Rhode Island,” he said.
Robertelli co-founded Admetsys in 2007, serving as chief operating officer of the medical robotics and artificial intelligence company through 2024. There, he helped drive the development of PrecisionOne, a real-time diagnostics and clinical robotics platform often described as an artificial pancreas, guiding it through three Food and Drug Administration clinical trials under Breakthrough Device Designation and to Conformité Européenne mark approval in Europe. Before that, he founded Intelligen LLC and its Asia-Pacific arm, commercializing ViewGuard and GearGuard technologies now embedded in millions of mobile devices worldwide. His career began in Johnson & Johnson’s Leadership Development Program, working across operations, supply chain, strategic marketing and new-product development.
“Building one breakthrough technology teaches you something humbling: no company does it alone,” Robertelli said.
In his first two years at RI Bio, he focused on member-driven priorities: expanding networking and startup support, launching an entrepreneur-in-residence pilot, and building educational programming around neuroscience, neurotech and combination products. He’s helped strengthen ties to the R.I. Life Science Hub and supported more than $45 million in state investment in lab and infrastructure projects, including Ocean State Labs.
“We’re not trying to out-Boston Boston – we’re offering something unique,” he said. “Collaboration, not competition, is how a state our size wins.”
